

Amikacin liposomal nebuliser dispersion 590mg (Arikayce®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2432	Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/03/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/amikacin-arikayce-resub-smc2432/>

Other Decision Specified

Date of ADTC 15/12/2021

Olopatadine 600 micrograms /mometasone 25 micrograms per actuation nasal spray (Ryaltris®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2418	In adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis. SMC restriction: for use where monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.	Not routinely available as there is a local preference for alternative medicines	15/12/2021

Web Links

<https://www.scottishmedicines.org.uk/medicines-advice/olopatadine-hydrochloride-and-mometasone-furoate-monohydrate-ryaltris-abb-s>

Other Decision Specified

Date of ADTC 15/12/2021

Ibrutinib 140mg, 280mg and 420mg film-coated tablets (Imbruvica®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2387	As a single agent for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy. SMC restriction: for use in patients who have received at least one prior therapy.	Available in line with local or regional guidance	18/05/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/ibrutinib-imbruvica-full-smc2387/>

Other Decision Specified

Date of ADTC 15/12/2021

Tafamidis 61mg soft capsules (Vyndaqel®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2426	For the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).	Not routinely available as not recommended for use in NHS Scotland	15/12/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/tafamidis-vyndaqel-resub-smc2426/>

Other Decision Specified

Date of ADTC 15/12/2021

Tirbanibulin 10mg/g ointment (Klisyri®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2395	Field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/03/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/tirbanibulin-klisyri-full-smc2395/>

Other Decision Specified

Date of ADTC 15/12/2021

Buprenorphine 74.2mg implant (Sixmo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2372	For substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/03/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/buprenorphine-implant-sixmo-full-smc2372/>

Other Decision Specified

Date of ADTC 15/12/2021

Anakinra 100mg solution for injection in a pre-filled syringe (Kineret®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2449	Treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.	Not routinely available as not recommended for use in NHS Scotland	15/12/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/anakinra-kineret-nonsub-smc2449/>

Other Decision Specified

Date of ADTC 15/12/2021

Nitisinone 2mg, 5mg, 10mg and 20mg hard capsules and 4mg/mL oral suspension (Orfadin®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2450	Treatment of adult patients with alkaptonuria (AKU).	Not routinely available as not recommended for use in NHS Scotland	15/12/2021

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/nitisinone-orfadin-nonsub-smc2450/>

Other Decision Specified

Date of ADTC 15/12/2021

Olaparib 100mg and 150mg film-coated tablets (Lynparza®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2368	In combination with bevacizumab for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.	Available in line with local or regional guidance	16/03/2022

Web Links

<https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-full-smc2368/>

Other Decision Specified

Date of ADTC 15/12/2021

Nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)

SMC Drug ID	Conditions	Decision	Date or Expected Date of Decision
SMC2394	In combination with ipilimumab for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts – decision expected by	31/03/2022

Web Links <https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-full-smc2394/>

Other Decision Specified

Date of ADTC 15/12/2021
